Desjardins, A., Randazzo, D., Chandramohan, V., Peters, K., Johnson, M., Landi, D., … Bigner, D. (2020). CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). In Neuro-Oncology (Vol. 22, pp. ii38–ii38). Oxford University Press (OUP). https://doi.org/10.1093/neuonc/noaa215.157

Desjardins, Annick, Dina Randazzo, Vidya Chandramohan, Katherine Peters, Margaret Johnson, Daniel Landi, Mustafa Khasraw, et al. “CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG).” In Neuro-Oncology, 22:ii38–ii38. Oxford University Press (OUP), 2020. https://doi.org/10.1093/neuonc/noaa215.157.

Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Landi D, et al. CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). In: Neuro-Oncology. Oxford University Press (OUP); 2020. p. ii38–ii38.

Desjardins, Annick, et al. “CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG).” Neuro-Oncology, vol. 22, no. Supplement_2, Oxford University Press (OUP), 2020, pp. ii38–ii38. Crossref, doi:10.1093/neuonc/noaa215.157.

Desjardins A, Randazzo D, Chandramohan V, Peters K, Johnson M, Landi D, Khasraw M, Threatt S, Bullock C, Herndon J, Lipp E, Sampson J, Friedman A, Friedman H, Ashley D, Bigner D. CTIM-23. A PHASE 1 TRIAL OF D2C7-IT IN COMBINATION WITH ATEZOLIZUMAB IN RECURRENT WHO GRADE IV MALIGNANT GLIOMA (MG). Neuro-Oncology. Oxford University Press (OUP); 2020. p. ii38–ii38.